Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News EMA approves Dupixent as first biologic for COPD with elevated eosinophils The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for… byPallavi MadhirajuJuly 7, 2024